Simris Alg AB (publ)
Simris Group AB (PUBL), a biotechnology company, develops, manufactures, and sells bioactive substances from microalgae in Sweden and internationally. It offers skincare products and pharmaceuticals; food ingredients; and Algae Omega-3, an omega-3 EPA and DHA line under the SIMRIS brand name. The company was incorporated in 2011 and is headquartered in Hammenhög, Sweden.
Simris Alg AB (publ) (SIMRIS-B) - Net Assets
Latest net assets as of December 2025: Skr-470.00K SEK
Based on the latest financial reports, Simris Alg AB (publ) (SIMRIS-B) has net assets worth Skr-470.00K SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr148.38 Million) and total liabilities (Skr148.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr-470.00K |
| % of Total Assets | -0.32% |
| Annual Growth Rate | N/A |
| 5-Year Change | -102.58% |
| 10-Year Change | -100.72% |
| Growth Volatility | 95.9 |
Simris Alg AB (publ) - Net Assets Trend (2012–2025)
This chart illustrates how Simris Alg AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Simris Alg AB (publ) (2012–2025)
The table below shows the annual net assets of Simris Alg AB (publ) from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr-470.00K | -108.33% |
| 2024-12-31 | Skr5.64 Million | -77.98% |
| 2023-12-31 | Skr25.61 Million | +11.20% |
| 2022-12-31 | Skr23.03 Million | +26.41% |
| 2021-12-31 | Skr18.22 Million | -61.58% |
| 2020-12-31 | Skr47.42 Million | +35.51% |
| 2019-12-31 | Skr35.00 Million | -12.03% |
| 2018-12-31 | Skr39.78 Million | -6.80% |
| 2017-12-31 | Skr42.68 Million | -34.66% |
| 2016-12-31 | Skr65.32 Million | +68.87% |
| 2015-12-31 | Skr38.68 Million | +295.64% |
| 2014-12-31 | Skr9.78 Million | +73.65% |
| 2013-12-31 | Skr5.63 Million | -7.41% |
| 2012-12-31 | Skr6.08 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Simris Alg AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 284928400.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr8.42 Million | % |
| Total Equity | Skr-470.00K | 100.00% |
Simris Alg AB (publ) Competitors by Market Cap
The table below lists competitors of Simris Alg AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Peria Karamalai Tea & Produce Company Limited
NSE:PKTEA
|
$6.04 Million |
|
FMS Enterprises Migun Ltd
TA:FBRT
|
$6.04 Million |
|
Ashley Services Group Ltd
AU:ASH
|
$6.04 Million |
|
ZAUIF
PINK:ZAUIF
|
$6.04 Million |
|
TC Traders Club Ltda
SA:TRAD3
|
$6.03 Million |
|
The Grounds Real Estate Development AG
XETRA:AMM
|
$6.03 Million |
|
Xeriant Inc
OTCQB:XERI
|
$6.03 Million |
|
Althea Group Holdings Ltd
AU:AGH
|
$6.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Simris Alg AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,641,000 to -470,000, a change of -6,111,000 (-108.3%).
- Net loss of 26,811,000 reduced equity.
- Other comprehensive income increased equity by 156,730,000.
- Other factors decreased equity by 136,030,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-26.81 Million | -5704.47% |
| Other Comprehensive Income | Skr156.73 Million | +33346.81% |
| Other Changes | Skr-136.03 Million | -28942.55% |
| Total Change | Skr- | -108.33% |
Book Value vs Market Value Analysis
This analysis compares Simris Alg AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr398.74 | Skr0.09 | x |
| 2013-12-31 | Skr232.42 | Skr0.09 | x |
| 2014-12-31 | Skr0.68 | Skr0.09 | x |
| 2015-12-31 | Skr2.68 | Skr0.09 | x |
| 2016-12-31 | Skr3.52 | Skr0.09 | x |
| 2017-12-31 | Skr2.11 | Skr0.09 | x |
| 2018-12-31 | Skr1.62 | Skr0.09 | x |
| 2019-12-31 | Skr1.56 | Skr0.09 | x |
| 2020-12-31 | Skr0.43 | Skr0.09 | x |
| 2021-12-31 | Skr0.15 | Skr0.09 | x |
| 2022-12-31 | Skr0.15 | Skr0.09 | x |
| 2023-12-31 | Skr0.11 | Skr0.09 | x |
| 2024-12-31 | Skr0.02 | Skr0.09 | x |
| 2025-12-31 | Skr0.00 | Skr0.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Simris Alg AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1660.12%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-109.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -47.11% | -443.85% | 0.10x | 1.10x | Skr-3.47 Million |
| 2013 | -70.16% | -195.51% | 0.32x | 1.12x | Skr-4.51 Million |
| 2014 | -86.44% | -15365.45% | 0.01x | 1.11x | Skr-9.43 Million |
| 2015 | -30.52% | -4172.08% | 0.01x | 1.44x | Skr-15.68 Million |
| 2016 | -29.62% | -2664.20% | 0.01x | 1.17x | Skr-25.88 Million |
| 2017 | -53.83% | -2698.05% | 0.02x | 1.27x | Skr-27.25 Million |
| 2018 | -60.26% | -3146.57% | 0.02x | 1.25x | Skr-27.95 Million |
| 2019 | -76.90% | -1544.06% | 0.03x | 1.49x | Skr-30.41 Million |
| 2020 | -53.99% | -1182.09% | 0.04x | 1.20x | Skr-30.35 Million |
| 2021 | -155.62% | -462.05% | 0.21x | 1.60x | Skr-30.18 Million |
| 2022 | -106.03% | -598.58% | 0.02x | 8.06x | Skr-26.73 Million |
| 2023 | -145.64% | -856.80% | 0.02x | 6.81x | Skr-39.87 Million |
| 2024 | -613.46% | -1197.40% | 0.02x | 27.84x | Skr-35.17 Million |
| 2025 | 0.00% | -1660.12% | 0.01x | 0.00x | Skr-26.76 Million |
Industry Comparison
This section compares Simris Alg AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Simris Alg AB (publ) (SIMRIS-B) | Skr-470.00K | -47.11% | N/A | $6.04 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |